-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Breast CancerDrug Details:Cellular immunotherapy is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Colon Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Colon CancerDrug Details:Cellular immunotherapy is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Pancreatic CancerDrug Details:Cellular immunotherapy is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Kidney Cancer (Renal Cell Cancer) Drug Details: Dresbuxelimab (AK-119) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Kidney Cancer (Renal Cell Cancer) Drug Details: HTL-0039732 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: Plocabulin (PM-184, PM-060184) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Kidney Cancer (Renal Cell Cancer) Drug Details: BNT-151 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: Tipifarnib (Zarnestra) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.